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The impact of cognitive performance  
on quality of life in individuals with 
Parkinson’s disease
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ABSTRACT. Background: Evidence points to the occurrence of cognitive impairment in all stages of PD, constituting a 
frequent and debilitating symptom, due to high impact on quality of life and mortality of patients. Objective: To correlate 
cognitive performance with quality of life in PD. Methods: The sample was drawn from a Movement Disorders Clinic of 
a reference hospital in Porto Alegre. Inclusion criteria were: PD diagnosis, according to the United Kingdom Parkinson’s 
Disease Society Brain Bank criteria for idiopathic PD (Hughes et al. 1992) and patient consent to participate. Patients with 
other neurological pathologies and those submitted to deep brain stimulation were excluded. The evaluation consisted 
of a cognitive testing battery (composed of eight tests for assessing cognitive performance), and a questionnaire on 
quality of life (PDQ-39) and depression (BDI). Results: The sample comprised 85 individuals with PD, with a mean age 
of 62.9 years (±10.7), mean disease duration of 10.4 years (±5.7), and mean educational level of four years (±4.3). 
There was a significant relationship between total score on the PDQ and all cognitive tests, showing that poor cognitive 
performance was correlated with poor quality of life. Moreover, a significant correlation was observed between cognitive 
tests and depression, H&Y, education level, and age. Conclusion: It may be concluded that the individuals with PD in 
this sample showed a correlation between poorer quality of life and worse cognitive performance. Poor performance 
was also correlated with more advanced stage, older age, low level of education and depression.
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IMPACTO DA PERFORMANCE COGNITIVA NA QUALIDADE DE VIDA DE INDIVÍDUOS COM DOENÇA DE PARKINSON
RESUMO. Embasamento: As evidências apontam a ocorrência de comprometimento cognitivo em todas as fases da 
doença de Parkinson (DP), sendo este um sintoma não motor frequente e incapacitante, devido ao alto impacto na 
qualidade de vida e mortalidade dos pacientes. Objetivo: correlacionar a performance cognitiva com qualidade de 
vida na DP. Métodos: A amostra foi oriunda de um Ambulatório de Distúrbios do Movimento de um hospital referência 
de Porto Alegre. Os critérios de inclusão utilizados foram ter diagnóstico de DP e consentir em participar do estudo. 
Exclui-se pacientes com outras patologias neurológicas ou pacientes com estimulação cerebral profunda. A avaliação foi 
composta por uma anamnese, bateria de testes cognitivos (composta por oito testes), questionários sobre qualidade de 
vida (PDQ-39) e depressão (BDI). Resultados: A amostra foi composta por 85 indivíduos com DP, com média de idade 
de 62,9 anos (±10,7), média do tempo de doença de 10,4 anos (±5,7) e média de escolaridade de 7,4 anos (±4,3). 
Verificou-se relação significativa entre escore total do PDQ com todos os testes cognitivos, demonstrando que pior 
performance cognitiva está relacionada com pior qualidade de vida. Além disso, foi observado correlação significativa 
entre os testes cognitivos com depressão, H&Y, escolaridade e idade. Conclusão: Pode-se concluir que na presente 
amostra indivíduos com DP apresentaram correlação entre pior qualidade de vida com pior desempenho cognitivo. Isto 
também foi observado com estágio avançado da doença, idade avançada, baixa escolaridade e depressão. 
Palavras-chave: cognição, doença de Parkinson, avaliação.
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INTRODUCTION
Characterized as a neurodegenerative disease with degeneration of dopamine neurons, particularly in 
the substantia nigra of the midbrain, Parkinson’s disease 
(PD) is the second-most-prevalent neurodegenerative 
disease worldwide.1,2 In Brazil, the prevalence of PD is 
3.3% in the elderly.
It is estimated that about 25%-38.2% of individu-
als in the early stages of the disease present cognitive 
impairment.3,4 The literature has clearly established the 
occurrence of cognitive impairment at all stages of PD, 
representing a common and debilitating symptom due 
to its high impact on quality of life and mortality among 
patients.3-7
Although there is a heterogeneous clinical presenta-
tion of cognitive decline in PD, in most cases changes 
in executive function, attention, visuospatial function, 
working memory, episodic memory, and psychomotor 
speed are observed, suggesting alteration in the frontal 
lobe or frontostriatal circuits.3-7
Risk factors for cognitive dysfunction in PD include 
advanced age, low education, worsening of motor symp-
toms, rigidity, postural instability, excessive daytime 
sleepiness (behavioral disorder of REM sleep), visual 
hallucinations and cerebral white matter disease.3,6
Given the high prevalence of cognitive decline, its 
severity and the influence of motor symptoms in PD, it 
is important to determine whether there is a characteris-
tic profile of cognitive changes for the different stages of 
PD. Thus, the aim of this study was to correlate cognitive 
performance with quality of life in Parkinson’s disease.
METHODS
A cross-sectional, observational, descriptive study of 
individuals diagnosed with Parkinson’s disease was 
conducted. The study was approved by the Research 
Ethics Committee of a reference hospital in Porto 
Alegre, under number 120399.
Sample. The sample was derived from a Movement 
Disorders Clinic of a reference hospital in Porto Alegre. 
Inclusion criteria were: PD diagnosis, according to the 
United Kingdom Parkinson’s Disease Society Brain 
Bank criteria for idiopathic PD,8 and patient consent to 
participate. Patients with other neurological patholo-
gies or previous treatment with deep brain stimulation 
surgery were excluded.
Procedures. The evaluation was conducted in a single 
session, consisting of anamnesis, cognitive testing 
battery, and application of the Modified Hoehn and 
Yahr Scale (H&Y).9 The cognitive battery was drawn 
from the list of recommendations of the Movement 
Disorders Society (MDS), consisting of:
Mini-Mental State Examination (MMSE): score ranges 
from 0 to 30 points, with higher scores indicating bet-
ter cognitive performance. Validated for Brazilian Portu-
guese, with normative reference values of ≥28 points for 
educational level >8 years; 26 for 5-8 years’ education; 
25 for 1-4 years; and 20 for illiterate individuals.10
Categorical verbal fluency (categorical FAS): evaluates 
the ability to search for and retrieve data established in 
long-term memory within a particular category, requir-
ing organizational skills, self-regulation and working 
memory. Validated for Brazilian Portuguese, with the 
following normative values: cut-off of 9 animals for indi-
viduals with educational level of ≤8 years and cut-off 
point of 13 animals for an educational level >9 years.11
Verbal fluency with phonological restriction (FAS): this 
test assesses executive function, language, and semantic 
memory. It is validated for Brazilian Portuguese.12
Rey Auditory Verbal Learning Test (RAVLT): this 
comprises assessment of immediate memory, besides 
short and long-term retention. Validated for Brazilian 
Portuguese.13
Montreal Cognitive Assessment (MoCA): this test 
investigates the individual’s skills in five areas: visuospa-
tial/executive, naming, memory, attention, abstraction, 
and guidance. The total score is the sum of all items with 
a maximum of 30 (best performance). It is validated for 
Brazilian Portuguese.14
Frontal Assessment Battery (FAB): This battery 
assesses executive functions, such as conceptualization, 
mental flexibility, programming, sensitivity to interfer-
ence, inhibitory control and environmental autonomy. 
The total score is the sum of all items, ranging from 0 
(worst performance) to 18 (best performance). It is vali-
dated for Brazilian Portuguese.15
Scales for Outcomes in Parkinson’s disease - Cognition 
(Scopa-cog): this instrument has been indicated as appro-
priate for evaluation of executive functions in individu-
als with PD. The battery consists of tasks that seek to 
evaluate the following cognitive functions: memory 
and learning, attention, executive functions, visuospa-
tial functions, memory. The score ranges from 0 (worst 
performance) to 43 (best performance) points. It is vali-
dated for Brazilian Portuguese.16
Trail Making Test (TMT): version A allows evaluation 
of processing speed and visual attention. Version B is 
used to measure an individual’s ability to manage com-
peting sources of data, revealing flexibility and planning, 
and also used as a measure of working memory.17
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Parkinson’s Disease Questionnaire-39 (PDQ-39): the 
appropriate instrument for assessing the quality of life 
of individuals with PD, translated for use in Brazil.
Beck Depression Inventory (BDI): this is a scale for 
measuring depression composed of 21 questions with 
scores ranging from 0 to 3 points, totaling 63 points. 
On the BDI, depression is defined as scores <15, mild 
depression 15-20 points, moderate-to-severe depression 
20-30 points, and severe depression 30-63 points.18
Modified Hoehn and Yahr Scale (H & Y - Degree of Dis-
ability Scale):9 it is an instrument that allows the classi-
fication of disability of individuals with PD. It comprises 
seven stages of classification, assessing severity based 
on global measures of signs and symptoms.
Statistical analysis. A descriptive analysis of all variables 
was conducted, expressed as mean and standard devia-
tion (SD). The Shapiro-Wilk normality test was applied 
to determine the homogeneity of variance. Spearman’s 
correlation test was used for the variables MMSE, 
RAVLT, Trails A, written trails A and education. Pear-
son’s correlation test was employed for symmetrical 
variables (age, disease duration, FAS, FAB, Scopa-cog). 
A 5% error was stipulated for all tests. The statistical 
program used was the Statistical Package for Social 
Sciences (SPSS) version 20.0.
RESULTS
The sample consisted of 85 individuals with PD. The 
mean age of the subjects was 62.9 years (±10.7), mean 
disease duration was 10.4 years (±5.7) and mean educa-
tion was 7.4 years (±4.3).
The significant correlation between quality of life 
and depression with cognitive performance is shown in 
Table 1.
The correlation between the variables age, level of 
education and disease duration with the results of cogni-
tive tests is shown in Table 2. The correlations between 
the H&Y scale stages and cognitive tests are given in 
Table 3. 
The Trail Making Test B version was excluded from 
the analysis because 67.0% of individuals failed in less 
than five minutes (300 seconds), which is the maxi-
mum time to record the test score. Thus, only a small 
number of patients remained for performing statistical 
correlations.
DISCUSSION
This study sought to apply a broad cognitive battery 
composed of eight tests, given the literature affirms 
the need to conduct a battery of comprehensive neuro-
psychological tests for accurate diagnosis of cognitive 
changes in PD.19 This is justified by the heterogeneity of 






p r p r
MMSE* 24.50 (±4.0) 0.004 –0.324 b 0.002 –0.326
FAS categorical* 13.45 (±4.9) 0.011 –0.284a 0.065 –0.203
FAS* 24.64 (±12.2) 0.007 –0.299a 0.004 –0.307
MOCA* 19.35 (±5.4) <0.001 –0.406a 0.010 –0.279
RAVLT a (a1-a5)* 25.07 (±9.7) 0.008 –0.296b 0.006 –0.299
RAVLT immediate (a6)* 4.13 (±2.9) 0.074 –0.202b 0.012 –0.272
RAVLT recent (a7)* 3.07 (±3.1) 0.009 0.292b 0.004 –0.308
FAB* 11.80 (±3.7) 0.019 –0.264b 0.019 –0.255
Trail A (seconds)* 11.06 (±6.3) 0.001 0.378b 0.088 0.190
Trail B (seconds)* 59.20 (±37.6) 0.028 0.339b 0.187 0.203
Scopa-cog* 14.00 (±4.9) 0.002 –0.345a 0.036 –0.233
a: Pearson’s correlation; b: Spearman’s correlation; * Results expressed as mean and standard deviation; r: correlation coefficient; p: p-value; H & Y: Hoehn and Yahr Scale; MMSE: Mini-Mental 
State Examination; FAS: Verbal Fluency; Montreal Cognitive Assessment: MOCA; FAB: Frontal Assessment Battery; RAVLT: Rey Auditory Verbal Learning Test; Scopa-cog: Scales for Outcomes in 
Parkinson’s disease-Cognition.
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clinical presentation of cognitive decline in PD, which 
can cause changes in several cognitive functions.3-7 
According to the literature,3,6,19-21 cognitive changes 
are a significant non-motor symptom in individuals with 
PD and significantly contribute to poor quality of life. 
Thus, it was important to study the impact of symp-
toms in our population as the cognitive performance 
data showed different impacts on quality of life. Data 
indicates that 15%-25% of newly diagnosed PD patients 
have mild cognitive impairment (MCI), and approxi-
mately 50% of those with PD develop dementia within 
the first ten years of diagnosis, rising to over 80% 20 
years after diagnosis.
According to the results for the sample, a signifi-
cant inverse correlation was found between quality of 
life (PDQ-39) and cognitive tests (MMSE, Fascat, FAS, 
MOCA, RAVLT, FAB and Scopa-cog) and a direct correla-
tion between QOL and the trails test. Thus, individuals 
with better quality of life had better cognitive perfor-
mance. The same was observed for depression, which 
showed a significant inverse correlation between the 
BDI test, and the MMSE cognitive tests, FAS, MOCA, 
RAVLT, FAB, and Scopa-cog, demonstrating that indi-
viduals with major depression had poorer performance 
on the cognitive assessments. 
These findings corroborate evidence in the litera-
ture22-26 showing that worse quality of life and depres-
sion are associated with worse cognitive performance 
or presence of dementia in individuals with PD. In the 
studies,22-25 there was a significant correlation between 
quality of life measured by PDQ-39 or PDQ- 8 and better 
performance on cognitive assessments.
Regarding depression, Klepac et al. (2008)22 observed 
a correlation between lower scores on the BDI with 
better scores on cognition and quality of life. Ng et al. 
(2015)25 found lower scores on cognitive tests in indi-
viduals with PD and depression when compared to 
patients without depression and to healthy controls. 
Furthermore, Wang et al. (2014) found that depression 
is a predictive risk factor for cognitive impairment in PD 
with an OR=1.98 and p=0.03.
Furthermore, the results revealed a positive correla-
tion between the MMSE, FAS, FAS categorical, MOCA, 
RAVLT, FAB and Scopa-cog and education, and a nega-
tive correlation of the Trail Making Test with education. 
Thus, the higher the educational level of individuals, the 
better the performance on cognitive tests. Regarding 
age, there was a negative correlation with the FAS, FAS 
categorical, MOCA, RAVLT, FAB and Scopa-cog and a 
positive correlation with the Trail Test. Thus, the higher 
the age of the individual worse their performance on 
cognitive tests. 
According to the literature, age is the biggest risk fac-
tor for developing dementia in PD.19,20 The key element 
Table 2. Correlation of age, education and disease duration with cognitive tests.
Variables Mean (SD)
Age** Educational level* Disease duration**
p r p r p r
MMSE* 24.50 (±4.0) 0.098 –0.182 <0.001 0.438 0.381 –0.115
FAS categorical** 13.45 (±4.9) 0.018 –0.258 <0.001 0.510 0.647 –0.060
FAS** 24.64 (±12.2) 0.004 –0.308 <0.001 0.552 0.260 –0.148
MOCA** 19.35 (±5.4) <0.001 –0.385 <0.001 0.535 0.107 –0.210
RAVLT a (a1-a5)** 25.07 (±9.7) <0.001 –0.397 0.002 0.335 0.910 0.015
RAVLT immediate (a6)* 4.13 (±2.9) <0.001 –0.389 0.006 0.300 0.787 0.036
RAVLT recent (a7)* 3.07 (±3.1) <0.001 –0.434 0.021 0.253 0.899 –0.017
FAB** 11.80 (±3.7) 0.001 –0.368 <0.001 0.532 0.248 –0.152
Trail A (seconds)* 11.06 (±6.3) 0.001 0.371 0.001 –0.437 0.789 0.036
Trail B (seconds) 59.20 (±37.6) – – – – – –
Scopa-cog** 14.00 (±4.9) 0.002 –0.331 <0.001 0.475 0.706 –0.050
*Spearman’s correlation; **Pearson’s correlation; r: correlation coefficient; p: p-value; H & Y: Hoehn and Yahr Scale; MMSE: Mini-Mental State Examination; FAS: Verbal Fluency; Montreal Cognitive 
Assessment: MOCA; FAB: Frontal Assessment Battery; RAVLT: Rey Auditory Verbal Learning Test; Scopa-cog: Scales for Outcomes in Parkinson’s disease-Cognition.
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Table 3. Correlation between PD stage and cognitive assessment.
Cognitive Tests H&Y Min Max
Percentiles
p25 50 75
MMSE 2 10 30 23.25 26 27 0.09
3 16 30 21 23 26.5
4 10 27 14 20 26.5
FAS categorical 2 4 31 11.5 14.5 19 0.077
3 3 22 10 11 17
4 4 18 6 10 14
FAS 2 4 54 20 26 35.5 0.09
3 3 49 13.5 22 35
4 2 39 3 16 28.5
MOCA 2 7 26 18.5 22a 23.75 0.04
3 9 30 14 17ab 22
4 3 21 7.5 14b 20
RAVLT 
a (a1-a5)
2 9 47 18 25 28.75 0.602
3 7 48 14 23 28.5
4 12 26 12.5 25 26
RAVLT 
immediate (a6)
2 0 9 2.25 3 5 0.357
3 0 11 1.5 3 6
4 0 5 0.5 1 4
RAVLT
recent (a7)
2 0 9 0.25 3 4 0.509
3 0 10 0 1 4.5
4 0 5 0 0 4
FAB 2 2 17 9.25 13a 15 0.025
3 5 18 8 11ab 13
4 3 12 3 7b 12
Trail A 2 4 46 7 8 12.75 0.063
3 6 888 8 11 15
4 12 15 12 13 15
Trail B 2 19 185 23 38 79 0.25
3 24 142 33 48 66.5
4 63 97 63 79 .
SCOPA 2 5 25 13 16a 18 0.01
3 3 22 9 12b 14.5
4 4 16 4.5 11ab 15.5
Kruskal-Wallis test; min: minimum; max: maximum; p: p-value; Different letters represent statistically different distribution. H & Y: Hoehn and Yahr Scale; MMSE: Mini-Mental State Examination; 
FAS: Verbal Fluency; Montreal Cognitive Assessment: MOCA; FAB: Frontal Assessment Battery; RAVLT: Rey Auditory Verbal Learning Test; Scopa-cog: Scales for Outcomes in Parkinson’s disease-
Cognition.
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is the current age of the patients as opposed to age at 
disease onset. Also, low educational level is also reported 
as a risk factor for dementia in this population.19 This 
justifies the correlation of older age and low education 
with worst performance on cognitive tests found in 
this sample. These data corroborate the Kandiah et al. 
(2014)3 study which found that patients with advanced 
age and lower education had poorer performance on 
cognitive tests. 
The factors advanced age and lower educational level 
were associated with worse cognitive performance in 
this sample, confirming the data found in the Hindle 
et al. (2015)20 longitudinal cohort study in individuals 
with PD. In the cited study, higher levels of education, 
socioeconomic status, and recent social engagement were 
associated with better overall cognition in the first evalu-
ation. After four years, normal cognition at baseline and 
higher levels of education were associated with better 
overall cognition over time. Older age and lower social 
commitment levels were associated with an increased 
risk of dementia. Individuals who developed dementia 
during the four years were older, had more severe motor 
symptoms and used the phone less at baseline.20
In addition to age and educational level, other risk 
factors have been found for cognitive dysfunction in PD, 
including lower scores on performance tests, rigidity, 
postural instability, increased daytime sleepiness and 
white matter disease.3,6,27,28
Regarding disease stage in our sample, there was a 
significant correlation between the H&Y and the MOCA, 
FAB and Scopa-cog cognitive tests, which are batteries 
assessing specific functions in the frontal lobe. According 
to the results, individuals with more advanced disease 
stage had poorer performance on the cited tests. These 
findings corroborate the literature which found a higher 
percentage of individuals with mild cognitive decline 
and moderate stages 3, 4 and 5 on the H&Y scale when 
compared to individuals without cognitive decline.3,29
In addition, these results corroborate the study by 
Varalta et. al. (2015)4 conducted in 21 individuals with 
PD, which found a significant correlation between bal-
ance ability and executive functions, cognitive impair-
ment and ability to switch attention between two tasks, 
functional mobility and cognitive impairment, and ver-
bal fluency and the ability to switch attention between 
two tasks. However, better cognitive performance was 
observed on the tests conducted when compared to this 
study, reporting median values of 14 points on the FAB, 
22 on the MOCA, and 29 points on the MMSE. These 
differences may be explained by the higher mean years 
of education in the study4 (10.6 years) compared to the 
present sample (7.4 years).
Furthermore, according to literature, cognitive 
decline in PD is more commonly associated with dys-
function in a single cognitive domain than multiple 
cognitive domains. Impairments in executive function, 
visuospatial function, attention, memory and psycho-
motor speed, suggest a frontal or frontostriatal change 
as the cause of these cognitive deficits.3,5,19,21 In our 
study population, cognitive dysfunction in multiple 
domains was observed, uncompensated by low educa-
tional impact.
Finally, we conclude that poor cognitive performance 
among individuals with PD was correlated with worse 
quality of life in this sample. This poor performance was 
also associated with more advanced stage, older age, 
lower level of education and depression.
Author contribution. Maira Rozenfeld Olchik: design of 
the study, data collection and intellectual contribution 
to the writing of the manuscript. Annelise Ayres: anal-
ysis of the data and writing of the manuscript. Marci-
elli Ghisi: data collection. Artur Schuh: design of the 
study and intellectual contribution to the writing of the 
manuscript. Carlos Rieder: intellectual contribution to 
the writing of the manuscript.
REFERENCES
1. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak 
E. Staging of brain pathology related to sporadic Parkinson’s disease. 
Neurobiol Aging. 2003;24(2):197-211.
2. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, 
Bloch DA, Nelson LM. Incidence of Parkinson’s disease: variation by 
age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015-22.
3. Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC. Montreal 
Cognitive Assessment for the screening and prediction of cogni-
tive decline in early Parkinson’s disease. Parkinsonism Relat Disord. 
2014;20(11):1145-8. 
4. Varalta V, Picelli A, Fonte C, Amato S, Melotti C, Zatezalo V, et al. 
Relationship between Cognitive Performance and Motor Dysfunction 
in Patients with Parkinson’s Disease: A Pilot Cross-Sectional Study. 
Biomed Res Int. 2015;2015:365959.
5. Schneider JS, Sendek S, Yang C. Relationship between Motor Symp-
toms, Cognition, and Demographic Characteristics in Treated Mild/
Moderate Parkinson’s Disease. PLoS One. 2015;10(4):1-11.
6. Lin CH, Wu RM. Biomarkers of cognitive decline in Parkinson’s disease. 
Parkinsonism Relat Disord. 2015;21:431-3.
7. Machado FA, Reppold CT. The effect of deep brain stimulation on motor 
and cognitive symptoms of Parkinson’s disease: A literature review. 
Dement Neuropsychol. 2015;9(1):24-31.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis 
of idiopathic Parkinson’s disease: a clinico-pathological study of 100 
cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. 
Neurology. 1967;17:427-42.
10. Bertolucci PHF, Brucki SMD, Campacci SR. Juliano Y. O Mini-Exame do 
Dement Neuropsychol 2016 December;10(4):303-309
309Olchik et al.    Quality of life in Parkinson’s disease
Estado Mental em uma população geral: impacto da escolaridade. Arq 
Neuropsiquiatr. 1994;52(1):1-0. 
11. Brucki SMD, Malheiros SMF, Okamoto IH, Bertolucci PHF. Dados norma-
tivos para o teste de fluência verbal categoria animais em nosso meio. 
Arq. Neuro-Psiquiatr. 1997;55(1):56-61. 
12. Benton AL, Hamsher K. Multilingual Aphasia Examination. AJA Associ-
ates 1989. 
13. Malloy-Diniz LF, Lasmar VAP, Gazinelli LSR, Fuentes D, Salgado JV. The 
Rey Auditory-Verbal Learning Test: applicability for the Brazilian elderly 
population. Rev Bras Psiquiatr. 2007;29(4):324-9.
14. Sarmento ARL. Apresentação e aplicabilidade da versão brasileira da 
MoCA (Montreal Cognitive Assessment) para rastreio de comprome-
timento cognitivo leve [dissertação]. São Paulo: Escola Paulista de 
Medicina da Universidade Federal de São Paulo. Programa de Pós-
graduação; 2009.
15. Beato RG, Nitrini R, Formigoni AP, Caramelli P. Brazilian version of the 
Frontal Assessment Battery (FAB). Dement Neuropsychol. 2007;1:59-65.
16. Carod-Artal FJ, Martínez-Martin P, Kummer W, Ribeiro LS. Psycho-
metric attributes of the SCOPA-COG Brazilian version. Mov Disord 
2008;23(1):81-7.
17. Carod-Artal FJ, Martinez-Martin P, Vargas AP. Independent validation 
of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian 
version. Mov Disord. 2007;22:91-8. 
18. Tombaugh TN. Trail Making Test A and B: Normative data stratified by 
age and education. Arch Clin Neuropsychol. 2004;19:203-14.
19. Babor TF, Biddle-Higgins JC, Saunders JB, Monteiro MG. AUDIT: The 
alcohol use disorders identification test: guidelines for use in primary 
health care. World Health Organization; 2001.
20. Cosgrove J, Alty JE, Jamieson S. Cognitive impairment in Parkinson’s 
disease. Postgrad Med J. 2015;91:212-20.
21. Hindle JV, Hurt CS, Burn DJ, Brown RG, Samuel M, Wilson KC, Clare 
L.The effects of cognitive reserve and lifestyle on cognition and dementia 
in Parkinson’s disease-a longitudinal cohort study. Int J Geriatr Psychi-
atry. 2016;31(1):13-23. 
22. van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, 
Chahine LM, et al. Conversion between mini-mental state examination, 
montreal cognitive assessment, and dementia rating scale-2 scores in 
Parkinson’s disease. Mov Disord. 2014;29(14):1809-15. 
23. Klepac N, Trkulja V, Relja M, Babic T. Is quality of life in non-demented 
Parkinson_s disease patients related to cognitive performance? A clinic-
based cross-sectional study. Eur J Neurol. 2008;15:128-33.
24. Leroi I, McDonald K, Pantula H, Harbishettar V.Cognitive Impairment in 
Parkinson Disease:Impact on Quality of Life, Disability, and Caregiver 
Burden. J Geriatr Psychiatry Neurol. 2012;25(4):208-14.
25. Jones JD, Hass C, Mangal P, Lafo J, Okun MS, Bowers D. The Cogni-
tion and Emotional Well-being indices of the Parkinson’s disease ques-
tionnaire-39: What do they really measure? Parkinsonism Relat Disord. 
2014;20(11):1236-41.
26. Ng A, Chander RJ, Tan LCS, Kandiah N. Influence of depression in 
mild Parkinson’s disease on longitudinal motor and cognitive function. 
Parkinsonism Relat Disord. 2015;21:1056-60.
27. Wang Q, Zhang Z, Li L, Wen H, Xu Q. Assessment of cognitive impair-
ment in patients with Parkinson’s disease: prevalence and risk factors. 
Clin Interv Aging. 2014;9:275-81.
28. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM, 
Middelkoop HA, van Hilten JJ. Cognitive impairment in Parkinson’s 
disease. J Neurol Neurosurg Psychiatry. 2007;78:1182-7. 
29. Kandiah N, Mak E, Ng A, Huang S, Au WL, Sitoh YY, Tan LC. Cerebral 
white matter hyperintensity in Parkinson’s disease: a major risk factor for 
mild cognitive impairment. Parkinsonism Relat Disord. 2013;19(7):680-3.
30. Amar K, Stack E, Fitton C, Ashburn A, Roberts HC. Fall frequency, 
predicting falls and participating in falls research: Similarities among 
people with Parkinson’s disease with and without cognitive impairment. 
Parkinsonism Relat Disord. 2015;21(1):55-60. 
